A fatal bacteremia caused by hypermucousviscous KPC-2 producing extensively drug-resistant K64-ST11 Klebsiella pneumoniae in Brazil by Campos, Tatiana Amabile de et al.
CASE REPORT
published: 21 September 2018
doi: 10.3389/fmed.2018.00265
Frontiers in Medicine | www.frontiersin.org 1 September 2018 | Volume 5 | Article 265
Edited by:
Dongsheng Zhou,






University General Hospital Attikon,
Greece
*Correspondence:
Tatiana Amabile de Campos
tatianadecampos@unb.br
Specialty section:
This article was submitted to
Infectious Diseases - Surveillance,
Prevention and Treatment,
a section of the journal
Frontiers in Medicine
Received: 27 April 2018
Accepted: 31 August 2018
Published: 21 September 2018
Citation:
de Campos TA, Gonçalves LF,
Magalhães KG, de Paulo Martins V,
Pappas Júnior GJ, Peirano G,
Pitout JDD, Gonçalves GB,
Furlan JPR, Stehling EG and




K64-ST11 Klebsiella pneumoniae in
Brazil. Front. Med. 5:265.
doi: 10.3389/fmed.2018.00265





Tatiana Amabile de Campos 1*, Laura Fernandes Gonçalves 1, Kelly Grace Magalhães 1,
Vicente de Paulo Martins 1, Georgios Joannis Pappas Júnior 1, Gisele Peirano 2,
Johann D. D. Pitout 2, Guilherme Bartolomeu Gonçalves 3, João Pedro Rueda Furlan 3,
Eliana Guedes Stehling 3 and André Pitondo-Silva 4
1Department of Cell Biology, Institute of Biological Sciences, University of Brasilia, Brasília, Brazil, 2Department of Pathology
and Laboratory Medicine, University of Calgary, Calgary, AB, Canada, 3Department of Clinical, Toxicological and
Bromatological Analysis, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto,
Brazil, 4 School of Dentistry, University of Ribeirão Preto, Ribeirão Preto, Brazil
We report a fatal bacteremia caused by Klebsiella pneumoniae in a 60–70-year-old
patient from Brazil. The genomic analysis of three isolates (from blood culture, nasal and
anal swabs) showed that the bacteremia was caused by a KPC-2 producing extensively
drug-resistant K64-ST11 hypermucousviscous K. pneumoniae (hmKP) harboring several
virulence and antimicrobial resistance genes. Although the isolates did not present
virulence markers associated with hypervirulent K. pneumoniae (hvKP), they showed
invasion and toxicity to epithelial Hep-2 cells; resistance to cell microbicidal mechanisms;
and blood and human serum survival, evidencing their pathogenic potential. This study
highlights the risk of infection caused by hmKp strains not characterized as hvKP
as well as the clinical implications and difficulty of treatment, especially in elderly or
immunocompromised patients.
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INTRODUCTION
Case Presentation
A 60–70-year-old patient, presenting a transverse colon neoplasm, underwent a left hemicolectomy
at a tertiary hospital located in Brazil. For 9 months prior to surgery, the patient presented
severe diarrhea (five to six episodes a day) and weight loss (14 kg). At anesthetic induction,
the patient received venous ciprofloxacin, metronidazole, and tazobactam. Four days later, after
discharge from the intensive care unit (ICU), he presented acute kidney injury, systemic arterial
hypertension, chronic atrial flutter and suspected septic shock. Explorative laparoscopy showed
anastomotic dehiscence and enteric fluid in the peritoneal cavity. The patient was promptly
transferred back to the ICU. A blood culture was requested and returned a negative result. At
this time, meropenem and amphotericin B were administered as antimicrobial therapy. Two days
later, infectious surveillance and dialysis were initiated. For 4 days the patient remained non-
febrile, clinically stable and septic shock was considered resolved. Therefore, amphotericin B was
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discontinued and meropenem was maintained as antibiotic
therapy. Five days later, the patient had a cardiac arrest followed
by a bradycardia episode. A cardiopulmonary resuscitation
with noradrenaline was performed with a positive response.
The patient was submitted to mechanical ventilation, and
subsequently developed a pulmonary purulent infection in the
orotracheal tube. Polymyxin B was introduced as antimicrobial
therapy. Eighteen days after hospitalization, the patient showed
deterioration in general health, presented bradycardia (not
atropine reversible), and eventually died due to cardiac arrest.
Bacterial Isolates
Seventeen days after patient hospitalization, blood, anal and nasal
swabs were collected and all three bacterial cultures were positive
for K. pneumoniae by the VITEK-2 system (bioMerieux Brasil)
(KpBSB-A, KpBSB-B, and KpBSB-C). All isolates showed the
hypermucoviscosity phenotype determined by the string test (1).
Bacterial Survival in Blood and Serum
All isolates were used to evaluate their capacity for survival
in human blood and serum (2). For this approach, bacterial
suspensions previously grown at 37◦C in Luria-Bertani (LB)
medium for 18 h, were incubated in 550 µL of human blood (107
bacterial cells) and in 550 µL human serum (108 bacterial cells)
at 37◦C. Aliquots of 10 µL from each inoculum were removed
at times 0, 30, 60, and 120min and plated in Agar MacConkey
medium (Kasvi). All plates were incubated at 37◦C for 18 h
for colony forming unit (CFU) recovery quantification. For the
assays, blood and serum were collected from five health donors.
All isolates were tested in triplicate for each donor.
The results showed that the CFU recovery increased 2 times
(2x) after 30min of incubation in blood and serum. After 60min,
the recovery decreased in blood for isolates BSB-A and BSB-
C, and increased for BSB-B (Figure 1A). All isolates showed an
increase in CFU count after 60min of incubation, and two of
them (BSB-A and BSB-C) after 120min of incubation in human
serum (Figure 1B). These results indicate that the isolates were
able to survive and grow in human serum and blood.
Infection of Hep-2 Cells by Bacterial
Isolates
Bacterial invasion, cytotoxicity, resistance to epithelial cells and
microbicidal mechanisms were evaluated with Hep-2 cells which
were infected by the isolates with multiplicity of infection 1:1,000
(Hep-2 cells: isolates) as described by Favre-Bonte et al. (3).
Following infection, the Hep-2 cells were incubated at 37◦C and
5% CO2. After 30min, the cells were washed with phosphate-
buffered saline and the DMEM (Dulbecco’s Modified Eagle’s
medium) (Gibco) medium was replaced by DMEM with 10
mg/mL of Gentamicin (Sigma Aldrich). Bacterial invasion and
intracellular survival were evaluated by CFU quantification
at 3, 6, and 24 h post infection (h.p.i.). Bacterial cytotoxicity
was determined by MTT (3-(4, 5-dimethylthiazolyl-2)-2, 5-
diphenyltetrazolium bromide) assays (Sigma Aldrich) at 3, 6, 24,
and 48 h.p.i; and Hep-2 microbicidal mechanisms by nitric oxide
(NO) quantification using Griess reagent (Promega) 24 h.p.i. All
assays were carried out in triplicate for all isolates.
All isolates showed cytotoxic activity by reduced Hep-2
viability at 3, 6, and 24 h.p.i. (Figures 1C–E). Interestingly, after
24 h.p.i., all Hep-2 infected cells recovered their cell viability.
About 15,000–20,000 CFUs were recovered from cells infected
by the three isolates at 3 h.p.i. (Figure 1F). For cells infected by
KpBSB-A, CFU recovery increased about 2x at 6 h.p.i (30,000)
and 0.5x at 24 h.p.i. (2,000) (Figure 1F). For cells infected by
KpBSB-B, CFU recovery remains at about 15,000 at 6 h.p.i and
increased 1.5x at 24 h.p.i (Figure 1F). Finally, for cells infected by
the KpBSB-C isolate, CFU recovery did not present alterations
(Figure 1F). These results showed that all isolates were able to
invade and survive within Hep-2 cells. Furthermore, KpBSB-A
and KpBSB-B also presented growth in Hep-2 cells.
All infected cells showed higher levels of NO at 24 h.p.i.
indicating the activity of microbicide mechanisms by Hep-2 cells
(Figure 1G). Together with invasion assays (Figure 1F) these
results suggest that all isolates are resistant to these microbicidal
cell mechanisms.
Antimicrobial Susceptibility Test
Antimicrobial susceptibility tests were performed for 38
different antibiotic disks according to the Clinical & Laboratory
Standards Institute (CLSI) (4) and the results showed
extensively drug resistant (XDR) isolates (5), remaining
susceptible only to aminoglycosides (amikacin, gentamicin,
tobramycin, streptomycin and kanamycin). Minimum inhibitory
concentration (MIC) was determined for polymyxin B and
colistin by the microdilution method in a 96-well plate according
to the CLSI (4), and the MIC values obtained for the three
isolates were 0.5µg/mL for both antibiotics, indicating that the
isolates were susceptible to them.
PCR Screening for Antimicrobial
Resistance Genes and Molecular Typing
Methods
Initial PCR screening for antimicrobial resistance genes
(6, 7) showed isolates producing blaKPC and blaSHV genes.
Plasmid-mediated colistin resistance genes, mcr-1 and mcr-2,
were not found (Table 1). According to multilocus sequence
typing (MLST) analysis (http://bigsdb.pasteur.fr/klebsiella/
klebsiella.html), the isolates belonged to ST11 associated with
the clonal group CG258 which is considered an international
high-risk sequence type of KPC-producing K. pneumoniae.
Enterobacterial Repetitive Intergenic Consensus-PCR (ERIC-
PCR) analysis (8) showed the isolates presented 100% genetic
similarity (Supplementary Material). The combination of the
ERIC-PCR, MLST, and antimicrobial susceptibility results
indicated that the three isolates were the same strain.
Whole Genome Sequence
Two isolates (KpBSB-A and KpBSB-B) were submitted to next-
generation sequencing on an Illumina NextSeq500 (150-bp
paired-end) using the Nextera XT DNA sample preparation
kit (Illumina, San Diego, CA, United States). The obtained
sequences were assembled using SPAdes version 3.9.0 (9). The
final assembly contained 92 scaffolds (>1,000 bp) and a total
length of 5.6Mb. The genomic sequences enabled the assignment
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FIGURE 1 | Biological characterization of the three hypermucousviscous Klebsiella pneumoniae isolates (BSB-A; BSB-B, BSB-C). (A) Bacterial blood survival
evaluation of CFUs (colony forming units) recovery after isolate incubation in blood for 30, 60, and 120min. (B) Bacterial human serum survival evaluation of CFUs
recovery after isolate incubation in serum for 30, 60, and 120min. (C–E) Hep-2 cells viability after different periods of infection by K. pneumoniae isolates. (F) Bacterial
invasion of Hep-2 cells by K. pneumoniae isolates evaluated by CFUs recovery after 3, 6, and 24 h of infection. (G) Nitric Oxide quantification in Hep-2 cells after 24 h
of infection by K. pneumonia isolates. Uns: Unstimulated cells (not submitted to bacterial infection). Control: unstimulated cells (not submitted to bacterial infection).
DMSO: positive control for citotoxicity. *p < 0.05; **p < 0.01; ***p < 0.001. All infected cells were compared to unstimulated cells (non infected cells).
of K. pneumoniae belonging to ST11, confirming our previous
observations.
Resistance genes and plasmid replicons were determined
in silico using the ResFinder and PlasmidFinder web services, (10,
11) and the Bacterial Isolate Genome Sequence Database (https://
pubmlst.org/software/database/bigsdb/) was used to predict
pathogenicity. Genome analysis showed that the isolates
presented capsular type K64 and detected resistance genes for
beta-lactam (blaKPC−2, blaSHV−11), sulfonamide (sul1, sul2),
tetracycline (tetA, tetD), and trimethoprim (dfrA1). Also, a
plasmid-mediated (qnrS1) and efflux pump complex (oqxA,
oqxB) for quinolone resistance were detected. The following
plasmid replicons were observed: IncR and ColRNAI, (IncN,
IncA/C2, and IncFIB-like) (Table 1). In addition, the search
for virulence factors detected genes related to the phenolate
siderophore Yersiniabactin (ybtA, ybtE, ybtP, ybtQ, ybtS, ybtT,
ybtU, ybtX), irp1, irp2 and fyuA. The irp2 gene is observed
in strains derived from urinary infections, bacteremia and
other sources, and is considered an important virulence factor
for extraintestinal infection establishment (12). Furthermore,
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mannose-specific adhesin subunit of type 3 fimbriaemrkABCDF
and mrkHIJ loci, able to mediate bacterial adhesion and biofilm
formation for several surface structures (13) were also detected
(Table 1). Previous studies have demonstrated that many strains
belonging to ST11 do not present the mucoviscosity-associated
genes rpmA/magA (14)
Statistical Analysis
For bacterial blood and serum survival and for Hep-2 bacterial
infection assays, the results were analyzed by ANOVA one
way using Prism GraphPad software version 6. P ≤ 0.05 were
considered significant.
BACKGROUND
K. pneumoniae is a Gram-negative bacilli associated with
opportunistic and nosocomial infections such as pneumonia,
meningitis and bacteremia. These strains are named classic
K. pnemoniae and have a polyssacharide capsule that promotes
their pathogenicty by phagocyte evasion. However, in the
last decades, a new variant named hypermucousviscous
K. pneumoniae (hmKP) has emerged and this scenario has
become extremely complicated by be frequent association with
abscess and devastating disseminated infections (15).
The hmKP strains produce a hypercapsule that promotes
the ability of bacterial spread and a propensity for metastatic
infection (1). Initially, these strains were also considered
hypervirulent (named hvKP/hmKP) by being able to infect
the non-immunocompromised population. Nowadays, several
researches have reported non-hypervirulent hmKP strains (16).
Among hvKP/hmKP strains, hypermucousviscous phenotype
is typically due to the increase of production of capsular
polysaccharide mediated primarily by the presence of specific
genes such as rmpA and magA (17). K1 and K2 are the
serotypes most associated with hvKP/hmKP, with K1 ST23 CC23
being considered a clonal group harboring specific virulence
factors. These strains are also considered hypervirulent, primarily
because of the association with the KPHPI patogenicity island
and with virulence factors such as aerobactin, and salmochelin
encoded by the pLVPK plasmid (17, 18). K2 isolates were also
considered hypervirulent, however they are genetically more
diverse (19).
Besides K1 and K2 serotypes, the virulence markers associated
with hvKP/hmKP strains are rmpA, rmpA2, aerobactin,
yersiniabactin, pld1, KpnO porin and a higher content of
capsular sialic acid. Despite hvKP/hmKP not belonging to
K1 or K2 and/or not harboring the rmpA/rmpA2 genes, they
represent a puzzle regarding the genetic factors responsible for
their particular phenotype (16). At the same time, evidence
suggests that hmKP strains may harbor other virulence factors
that promote their survival and spread in the host (16).
The prevalence of antibiotic resistance in hmKP and
hvKP/hmKP strains is rare compared with the high prevalence
presented by classic K. pneumoniae isolates (15, 17). However,
reports of antibiotic-resistant hmKP and hvKP/hmKP are
increasing worldwide and multidrug-resistance has been
reported in Asia, Europe and America (17). Difficulties on
managing carbapenem-resistant hmKP and hmKP/hvKP
infections could turn these strains into the next worldwide
“superbug” (17). Here we characterized three hmKP KPC-
XDR isolates from a patient with bacteremia after a sepsis due to
hemicolectomy surgery. The bacteremia was fatal and the isolates
were obtained from blood, nasal and anal swabs. The results
here obtained can contribute to understanding of the pathogenic
mechanisms related to hmKP.
DISCUSSION
Sepsis is a common complication observed after colectomy
surgery among elderly persons (20). An implication of this
scenario is surgical site infections, where K. pneumoniae is one
of the most likely organisms to be encountered (21). These
infections are successfully treated by antibiotic therapy, however
the presence of resistant or multidrug resistant strains can be
associated with bloodstream bacterial dissemination (22). Here
we reported a case of a sepsis episode in a 60–70-year-old patient,
after a hemicolectomy surgery followed by bacteremia caused by
a KPC-2 XDR K. pneumoniae strain.
Four days after presenting sepsis the patient remained
non-febrile and clinically stable and the sepsis episode was
considered resolved. However, the bacterial infection showed
high progression and after 15 days, and K. pneumoniae
were isolated from blood, nasal and anal cultures. All
isolates were identified as KPC-XDR, ST11, and presented
the same ERIC-PCR profile (Supplementary Material) and
hypermucousviscous phenotype, suggesting that the bacteremia
was caused by one strain presenting high spread potential.
The anastomotic dehiscence and enteric fluid in the peritoneal
cavity indicate that the source of bacteremia could be associated
with the surgical site infection due to the colectomy, where
the XDR-KPC strain could be present in the intestine of the
patient. On the other hand, the pulmonary purulent infection
in the orotracheal tube developed after mechanical ventilation
suggests that bacteremia could be acquired due to hospital
equipment. KPC infections have been reported in hospitals in
Brazil, including those located in the geographic area of the
isolates (23). However, we cannot confirm these hypotheses
because we do not have previous bacterial culture from the
patient and/or other isolates studied from the ICU hospital.
Previous case reports from bacteremia caused by XDR
K. pneumoniae strains showed that these infections were mostly
observed in elderly patients, mainly among those exposed to
invasive procedures harboring malignant and chronic diseases
(24–26). As observed in our report, the strains belonged to
high spreading STs such as ST258 (26) and ST11 (25), which
we frequently reported as causing bloodstream infections (BSI).
MLST analysis showed that the isolates belonged to ST11 CG258.
ST11 is a high-risk clone associated with KPC dissemination
and is commonly found in Brazil. This ST has been associated
with dissemination of KPC-KP by hmKP and hvKP strains from
different regions of Brazil (27). In our case report, we also
identified several virulence markers, primarily iron capitation
systems frequently associated with hypervirulent K. pneumoniae
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TABLE 1 | Data on the virulence and resistance genes and plasmid replicons, obtained by draft genome analysis of K. pneumoniae isolates from the study.
Isolate Source Genes found Replicon
Resistance Virulence
Kp-BSB-A Hemoculture blaSHV−11, blaKPC−2, fosA, sul1, sul2,
dfrA1, oqxA, oqxB, qnrS1, tetA, tetD
ybtS, ybtX, ybtQ, ybtP, ybtA, Irp1, Irp2,
ybtU, ybtT, ybtE, psn, fyuA, mrkA, mrkB,
mrkC, mrkD, mrkE, mrkH, mrkI, mrkJ, iutA
IncA/C, CoIRNA1, IncN, IncR, IncFIB (pKPHS1)
(15). The association between the risk of KPC and multidrug
resistance dissemination makes this ST even more worrying.
XDR- K. pneumoniae BSI are considered a huge health
concern because of the low or absent options for treatment.
Genomic analysis showed that strains harbored beta-lactamases
(SHV), carbapemases (KPC-2) and genes conferring resistance
to fosfomicin (fosA), sulfamtoxazole (sul1, sul2), trimethoprim
(dfrA1), tetracycline (tetDb) and to quinolones (oqxA, oqxB,:
qnrS1) (Table 1). This analysis confirmed the resistance profile
detected by antimicrobial susceptibility: that bacteremia was
caused by an XDR K. pneumoniae, and aminoglycosides could
be the unique option for therapy. However the negative
result obtained from the first blood culture and the patient’s
clinical stability had masked the KPC-XDR infection. Therefore,
meropenen prescription was continued and may contribute to
the spread of infection. For sepsis, clinical symptoms frequently
manifest in the absence of a positive culture resulting in diagnosis
delay (28). As observed here, negative culture contributed to
the wrong antibiotic prescription and was fatal to the patient.
Periodical blood collection for bacterial culture could be an
approach used for similar cases in order to detect silent
infections, mainly in areas with previous KPC K. pneumoniae
reports.
For BSI, monotherapy has been considered low efficacy and
antibiotic combinations have shown better effectiveness due
to synergic action (29). Therefore, carbapenem monotherapy
should be avoided, manly if its resistance was previously reported
in the hospital. Triple combination with polymyxin-colistin
has shown improved efficacy to carbapenamases-producing
K. pneumoniae infections treatment (29). On the other hand the
hypercapsule of the isolates could be an obstacle to this approach
since the increase of capsular polysaccharide production has been
associated with polymyxin susceptibility reduction (30).
All isolates were classified as K64, a capsular serotype not
yet reported with hypervirulence. Furthermore, these strains did
not present several molecular virulence markers associated with
hvKP strains (16). However, all isolates presented abilities to
invade epithelial cells, to resist their microbicidal mechanisms,
and showed cytotoxic potential (Figures 1C–E). These features
suggest that the isolates harbor factors that promote epithelial
host cells colonization and infection dissemination. Additionally,
it has been shown that this strain may carry different virulence
determinants from those already described for hmKP/hvKP.
More characterization is needed to identify whether the strain
here studied is also an hvKP with pathogenicity mechanisms not
yet described.
The diagnosis difficulties after a sepsis episode, the high
pathogenic potential presented by the isolates, the antibiotic
resistance promoted by genes and by hypercapsule production,
and the patient’s debility contributed to the fatal character
of the bacteremia. Moreover, the high prevalence of KPC-
2 in Brazil demonstrates the high spread and colonization
capacity presented by these strains (31). Considering all these
variants, immunization programs for high-risk patients can be
a precious tool to decrease the fatal potential of XDR-KPC K.
pneumoniae. Successful immunization approaches such as the
Egyptian vaccine offered broad spectrum coverage of more than
85% to all tested isolates (32) and can be a good alternative to
improve the outcome for a high risk patient.
CONCLUDING REMARKS
In summary, we described a fatal case of a hypermucousviscous
KPC-2 producing XDR ST11 K. pneumoniae, which occurred
in Brazil. Resistance to carbapenems and KPC-2 are extensively
reported in K. pneumoniae isolates from this region (30). As
shown by the antimicrobial susceptibility test results, the use
of aminoglycosides could have been a good therapeutic choice.
However, the initial patient clinical stability, after meropenem
treatment for sepsis control, may have hidden the bacteremia
progress by XDR-K. pneumoniae. Moreover, the virulence may
have also contributed to the bacteremia evolution. Periodical
blood collection for bacterial culture could be an approach used
for similar cases in order to detect silent infections, mainly in
areas with previous KPC K. pneumoniae infection reports.
This Whole Genome Shotgun project has been deposited
in ENA (European Nucleotide Archive) under the accession
number PRJEB24576.
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